Thermo Fisher Scientific reported second-quarter revenue of $10.86 billion, a 3% increase from a year earlier and ahead of the $10.69 billion analysts expected. Organic revenue, which strips out currency effects and acquisitions, rose 2%, also topping projections. Adjusted net income reached $2.03 billion, translating to earnings of $5.36 a share, versus consensus estimates of $5.24. On a GAAP basis, diluted earnings per share rose 6% to $4.28. Adjusted operating income improved to $2.38 billion. Chief Executive Officer Marc N. Casper said the company had made “very good progress through the halfway point in the year,” citing new product launches in mass spectrometry and cryo-electron microscopy as contributors to market-share gains. Thermo Fisher plans to provide updated 2025 financial guidance during its earnings call later today. The stock rose about 2% in pre-market trading after the results beat expectations.